Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.

Butler, JORCID logo; Filippatos, GORCID logo; Siddiqi, TJ; Ferreira, JPORCID logo; Brueckmann, MORCID logo; Bocchi, EORCID logo; Böhm, MORCID logo; Chopra, VKORCID logo; Giannetti, NORCID logo; Iwata, T; +14 more...Januzzi, JLORCID logo; Kaul, SORCID logo; Piña, ILORCID logo; Ponikowski, PORCID logo; Rauch-Kröhnert, UORCID logo; Shah, SJORCID logo; Senni, M; Sumin, MORCID logo; Verma, S; Zhang, JORCID logo; Pocock, SJ; Zannad, FORCID logo; Packer, MORCID logo; Anker, SDORCID logo and (2022) Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation, 146 (14). pp. 1046-1055. ISSN 0009-7322 DOI: 10.1161/CIRCULATIONAHA.122.059755
Copy

BACKGROUND: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). METHODS: The effects of empagliflozin on the primary outcome of cardiovascular death or hospitalization for HF and on secondary outcomes (including total HF hospitalization, cardiovascular and all-cause mortality, and Kansas City Cardiomyopathy Questionnaire scores) were compared in women and men in the overall cohort and in subgroups defined by left ventricular ejection fraction (41%-49%, 50%-59%, and ≥60%). The effects of empagliflozin on physiological measures, including changes in systolic blood pressure, uric acid, hemoglobin, body weight, and natriuretic peptide levels, were also assessed. RESULTS: Of the 5988 patients randomized, 2676 (44.7%) were women. In the placebo arm, women tended to have lower risk for adverse outcomes, including a lower risk of all-cause mortality (hazard ratio, 0.69 [95% CI, 0.56, 0.84]). Compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for HF to a similar degree in both sexes (hazard ratio, 0.81 [95% CI, 0.69, 0.96] for men; and hazard ratio, 0.75 [95% CI, 0.61, 0.92] for women; Pinteraction=0.54). Sex did not modify the relationship between empagliflozin and outcomes across ejection fraction groups. Similar results were seen for secondary outcomes and physiological measures. Compared with placebo, empagliflozin improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score to a similar extent in both sexes (1.38 for men versus 1.63 for women at 52 weeks; Pinteraction=0.77); the results were similar for Kansas City Cardiomyopathy Questionnaire overall summary score and total summary score. CONCLUSIONS: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03057951.


picture_as_pdf
Butler_etal_2022_Effects-of-empagliflozin-in-women.pdf
subject
Published Version
Available under Creative Commons: Attribution 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads